No Data
Inventiva's Strategic Moves at Upcoming General Meeting
Inventiva Announces The Data Monitoring Committee Recommended To Continue The Clinical Trial Without Modification Of The Current Protocol, Based On The Pre-planned Review Of Safety Data
Inventiva Announces The Recommendation Of The Fifth DMC Of The NATiV3 Phase 3 Clinical Trial With Lanifibranor In Patients With MASH
Inventiva Announces Abstract From LEGEND, Phase 2 Trial, Evaluating Lanifibranor In Combination With Empagliflozin In Mash At The Aasld The Liver Meeting 2024
Top Premarket Decliners
Inventiva's 2024 Interim Financial Highlights and Prospects
No Data
No Data